20/20 Biolabs, Inc. · NASDAQ:AIDX
20/20 Biolabs — 20/20 GeneSystems — Reg A Offering (2018)
15 slides from 20/20 Biolabs's offering presentation, Jul 11, 2018
Slide 1: 20/20 Gene Systems Investor Deck 2018
([KLELW 20/20 Gene Systems Investor Deck 2018
Slide 2: What we do and why we do it
What we do: Develop and commercialize diagnostic tests for the early detection of cancer to improve outcomes Why we do it: To reduce cancer deaths in the U.S. and around the world 2
Slide 3: We started with PAULA's Test
We started with PAULA’s Test 20/20 GeneSystems developed PAULA’s Test, a blood test for early detection of lung cancer. PAULA’s Test is meant for use in patients at high risk of lung cancer due to long term smoking. PAULA’s Test can help detect lung cancer in patients without symptoms, even at the e
Slide 4: We shifted our focus to a more comprehensive solution: OneTest
We shifted our focus to a more comprehensive solution: OneTest Introducing this year what we believe to be the first multi-cancer early detection blood test powered by machine learning algorithms built with data from tens of thousands of individuals tested before being diagnosed with cancer Disclaim
Slide 5: OneTest: Early cancer screening blood test system for multiple cancers
OneTest: Early cancer screening blood test system for multiple cancers Among the first blood tests available in North America for the early detection of up to 5 or more otherwise deadly cancers using a single specimen (Lung, Liver, Pancreatic, Ovarian, Prostate, and others) Biomarker tests are subst
Slide 6: Our unique approach: 20/20 Hindsight
Our unique approach: 20/20 Hindsight™ 1. Tumor Biomarkers 3. Machine Learning 4. Organ Systems where Cancer risk warrants follow-up imaging 2. Clinical Parameters 1. 1. Applying different weights to the biomarkers in the panel and generating a combined score 2. 2. Integrating and giving weight to cl
Slide 7: Competitive advantages
Competitive advantages We believe 20/20 enters the market with a lead over competitors due to validation in a real-world data set As tests are sold, outcome data will be collected under an IRB approved clinical study and fed back into our algorithm for continuous learning and improvements Building g
Slide 8: Commercialization strategy
Commercialization strategy Strategy Scaling in U.S. through Channel Partners Market test directly to consumers who purchase for ~$200 and take test to physicians of their choice (In preliminary discussions with each of the below companies as of May 2018) (B2C2B) Some physicians will then offer test
Slide 9: Commercialization strategy: Strategic partners
Commercialization strategy Strategy Strategic partners Market algorithm (SaaS) to Hospital and Stand- alone Health Check Centers (B2B2C) Largest health insurance company in China Establishing “Beachhead” in Taiwan, source of Leader in using AI for healthcare in China: Good Doctor App has 150 million
Slide 10: The opportunity is now
The opportunity is now Pre-Revenue, Public Cancer Detection Companies = $125mm+ Market Cap Company Name Exchange: Cancer Test Revenue Market Cap Symbol (2017 est.) (March 31, 2018) Immunovia IMMNOV: Blood test for early detection $18K $321 Million Stockholm of pancreatic cancer Exchange VolitionRx N
Slide 11: U.S. Sales Goals: Number of tests
U.S. Sales Goals: Target: 25 million Americans getting a yearly OneTest by 2025 Number of tests Disclaimer: These statements reflect management’s current views and are meant for illustrative purposes. They do not 11 represent guarantees of future results, levels of activity, performance, or achievem
Slide 12: Potential exit strategy partners based on sub-industry
Potential exit strategy partners based on sub-industry We have had preliminary conversations with four of the below companies Cancer Biomarker Clinical Laboratory AI for Healthcare Global Leaders Leaders Global Leaders Disclaimer: These statements reflect management’s current views and are meant for
Slide 13: The team
The team Jonathan Cohen — Founder & CEO Under Mr. Cohen’s leadership, 20/20 GeneSystems has brought in approximately $6 million in grant funding and launched two successful products, a kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the
Slide 14: In summary: our value proposition as an investment opportunity
In summary: our value proposition as an investment opportunity Potential to save and Offering solution to High barriers to entry Robust M&A market with extend lives multi-billion market for competitors due to potential suitors from that benefits adults data acquisition lead both healthcare and IT wo
Slide 15: Thank you
Thank you 20/20 GeneSystems Investor Deck - 2018